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Abstract
The past decade has brought substantial advances in the 
management of inflammatory bowel diseases (IBD). The 
introduction of tumor necrosis factor (TNF) antagonists, 
evidence for the value of combination therapy, the recog­
nition of targeting lymphocyte trafficking and activation 
as a viable treatment, and the need for early treatment of 
high-risk patients are all fundamental concepts for current 
modern IBD treatment algorithms. In this article, authors 
review the existing data on approved biologicals and 
small molecules as well as provide insight on the current 
positioning of approved therapies. Patient stratification for 
the selection of specific therapies, therapeutic targets and 
patient monitoring will be discussed as well. The thera­
peutic armamentarium for IBD is expanding as novel and 
more targeted therapies become available. In the absence 
of comparative trials, positioning these agents is becoming 
difficult. Emerging concepts for the future will include an 
emphasis on the development of algorithms which will 
facilitate a greater understanding of the positioning of 
novel biological drugs and small molecules in order to 
best tailor therapy to the patient. In the interim, anti­TNF 
therapy remains an important component of IBD therapy 
with the most real-life evidence and should be considered 
as first­line therapy in patients with complicated Crohn’s 
disease and in acute­severe ulcerative colitis. The safety 
and efficacy of these ‘older’ anti­TNF therapies can be 
optimized by adhering to therapeutic algorithms which 
combine clinical and objective markers of disease severity 
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Core tip: Anti­tumor necrosis factor therapy should be 
considered as first­line therapy in patients with com­
plicated Crohn’s disease and in acute­severe ulcera­
tive colitis. Beyond these specific circumstances, the 
positioning of novel biologics and small molecules de-
pends on the patient’s medical history, preference and 
disease phenotype. The efficacy and safety of using 
immunomodulatory therapy can be enhanced by ad­
hering to therapeutic algorithms and using a ‘treat­to­
target’ approach. The risks for adverse events due to 
poor disease control outweigh the risks associated with 
early aggressive therapy. In the setting of clinical and bio­
chemical remission, following at least 6 mo of combined 
immunosuppressive therapy, consideration can be made 
to withdrawing thiopurine therapy in the correct patient 
with close follow­up. 
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INTRODUCTION
Therapeutic trials for inflammatory bowel disease 
(IBD) began nearly 100 years after the first case re­
port of IBD was published by Sir Samuel Wilks in 
1859 who used the term “ulcerative colitis (UC)” to 
describe a condition similar to what is understood as 
UC today[1]. Approximately 10 years following the ori­
ginal study by Sir Sidney Truelove which revealed the 
efficacy of corticosteroid therapy in UC, the first clinical 
trial evaluating steroids in Crohn’s disease (CD) was 
conducted in 1966 by Jones and Lennard­Jones[2]. Prior 
to these landmark trials, the treatment of IBD was 
limited to supportive care and surgical intervention. 
Knowledge regarding the adverse effects of chronic 
steroid therapy in UC ultimately led to the first positive 
double blind randomized controlled trial (RCT) evaluating 
the efficacy of sulfasalazine in 1962[3,4]. Unfortunately, 
many patients were unable to tolerate the side­effects 
from sulfasalazine which prompted additional studies 
to uncover the active ingredient, 5ASA[5]. Since, 5ASA 
has repeatedly demonstrated its efficacy and improved 
safety profile as compared to sulfasalazine in mild to 
moderate UC[6­8]. In contrast, 5ASA therapy has been 
abandoned in CD due to its inability to prevent quiescent 
disease relapse[9]. As steroid­refractory disease became 
more prevalent, reports on the use of ciclosporin began 
appearing and the first successful trials were conducted 
in 1989 and 1994 for steroid resistant severe CD and UC, 
respectively[10,11]. Due to ciclosporin’s narrow therapeutic 
window, alternative steroid-sparing agents such as thio-
purines were investigated. Although they have demon­
strated fair efficacy in IBD, it may take up to 3-6 mo 
for them to reach their full therapeutic effect thereby 
limiting their potential as a strong induction agent[12]. 
Despite their slow onset of action and risks, thiopurines 
may be used strategically to reduce immunogenicity 
associated with biologic therapy and augment the rate 
of remission[13,14] Budesonide, a corticosteroid which 
undergoes significant first­pass metabolism in the liver 
resulting in low systemic exposure, has also established 
its position in the therapeutic armamentarium since 
Rutgeerts et al[15]’s original study demonstrating its non­
inferiority to prednisolone therapy for CD patients in 
1994. Budesonide has since repeatedly demonstrated 
its efficacy and safety making it the preferred means of 
inducing remission in patients with mild Crohn’s ileitis[16]. 
A newer formulation with a delayed release (budesonide­
MMX©) can be efficacious in moderate UC as well[17]. 
Alongside the advent of new biological therapies, 
the therapeutic approach has evolved over the past 
decade to include the use of objective markers of disease 
severity and response to therapy in tandem with the 
historical clinical scores[18,19]. In this article, authors re-
view the existing data and provide a rationale for the 
positioning of the ‘old’ and ‘new’ biologicals and small 
molecules. Strategies for the use of available therapies 
based on recent guidelines will be reviewed. 
CD
Anti-tumor necrosis factor
Infliximab: Four years after the FDA approved the 
use of infliximab in CD, the first large RCT; ACCENT I, 
was published in 2002 which evaluated infliximab main-
tenance therapy in 573 patients with a CDAI of at least 
220 whom had responded well to an initial infusion of 
infliximab[20]. At the 30 and 54 wk follow-up, patients 
receiving infliximab maintenance therapy were more 
likely to be in remission (CDAI < 150) as compared to 
those without maintenance therapy (30 wk: OR = 2.7, 
95%CI: 1.6-4.6) with a similar incidence of infection 
across all groups[20]. Besides demonstrating infliximab’s 
efficacy, this study also provided a rationale for dose 
escalation in patients losing response to therapy[21]. 
Although effective for luminal disease, it was unclear if 
infliximab would also be effective for fistulising disease, 
thus the ACCENT Ⅱ trial was published 2 years later 
which included 306 patients with one or more draining 
abdominal or perianal fistulas of at least 3 mo duration[22]. 
In this trial, the patients who were undergoing infliximab 
maintenance therapy demonstrated a significant fis­
tula response wherein 36% (vs 23%, P = 0.009) had 
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complete resolution of fistula draining at 54 wk[22]. 
Additionally, ACCENT Ⅱ demonstrated a significant re­
duction in the requirement for hospitalization and surgery 
due to fistulising disease (8.6% vs 18.9%, P < 0.05)[23]. 
Early initiation of infliximab was further supported in 
a large study conducted by the GETAID group which 
evaluated the use of dual therapy vs monotherapy over 
52 wk in 113 steroid­dependant CD patients[13]. Both 
GETAID and ACCENT-Ⅰ studies identified incongruence 
amongst endoscopy and clinical scores, such as the 
CDAI. In a sub-study of ACCENT-Ⅰ, 18% of moderate 
to severe CD patients as determined by the CDAI score 
had no active CD on endoscopy[24]. This prompted a ratio­
nale to include more objective end points and markers 
of disease severity (e.g., CRP and mucosal healing) in 
future studies, as was included in the Study of Biologic 
and Immunomodulator Naive Patients in Crohn’s Disease 
(SONIC) conducted in 2010[14]. In this landmark RCT 
involving 508 biologic­ and immunosuppressive­naïve 
patients, the superiority of infliximab over azathioprine 
as well as the therapeutic advantage of combining 
therapies over monotherapy with either infliximab or 
azathioprine alone at the 30 and 50 wk follow­ups was 
demonstrated.[14]. 
Adalimumab: In an attempt to possibly reduce the 
immunogenic responses induced by chimeric anti­
bodies, such as infliximab which contains 25% mouse 
sequences, adalimumab was designed as the first fully 
human monoclonal antibody against tumor necrosis 
factor (TNF)-alpha[25]. The results of three pivotal trials 
(CLASSIC­Ⅰ, CHARM and GAIN) established regu-
latory approval of adalimumab for the induction and 
maintenance of remission of CD in 2007. CLASSIC­Ⅰ 
was the first human trial to evaluate induction of remis-
sion using adalimumab in 299 moderate to severe CD 
patients naïve to anti-TNF therapy[26]. A linear dose­
response curve was appreciated at the 4 wk follow-up, 
with the greatest clinical remission rate associated with 
the highest dose studied (160 mg and 80 mg at weeks 
0 and 2, respectively)[25]. As a ceiling effect was not 
achieved, it is unclear if higher dosing would be more 
efficacious, studies evaluating this are underway. The use 
of adalimumab as a second line induction agent following 
the failure of infliximab due to intolerance or poor re­
sponse was evaluated in the GAIN trial which included 
325 patients who had either lost response or become 
intolerant to infliximab[27]. At the 4 wk follow-up, 21% (34 
of 159) of patients in the adalimumab group vs 7% (12 
of 166) of those in the placebo group achieved clinical 
remission.
The efficacy of adalimumab for maintenance therapy 
was evaluated in the CLASSIC­Ⅱ and CHARM studies. 
CLASSIC­Ⅱ followed up with 276 patients from the 
CLASSIC­Ⅰ study at 56 wk after randomizing patients 
to receive maintenance dosing or placebo. A greater 
proportion of patients receiving adalimumab 40 mg 
SC weekly or biweekly were in remission as compared 
to those receiving placebo (83% and 79% vs 44%, 
respectively)[28]. Additionally, although most patients 
responded to therapy within the first week, some pa-
tients only responded to therapy after week 12[28]. 
This suggests that an observational period may need 
to occur prior to modifying therapy in patients who do 
not respond to induction following 1 wk. In the largest 
open-label study, CHARM enrolled 854 patients in order 
to evaluate the efficacy of adalimumab for induction 
and maintenance in CD patients not responding to alter­
native immunosuppressive therapy, including those 
whom had failed infliximab[29]. Although the induction 
dose of adalimumab was half of that provided in the 
CLASSIC trials, the response rate was similar. At week 
56, biweekly and weekly dosing was equally effective at 
maintaining remission as compared to placebo (36% and 
41% vs 12%, respectively). Of note, a greater proportion 
of patients receiving placebo discontinued treatment 
due to adverse events as compared to those receiving 
adalimumab[29]. This suggests the risks of complications 
associated with poorly controlled disease outweigh the 
risks associated with therapy. To corroborate the find­
ings from the previous studies demonstrating clinical 
remission, the EXTEND trial conducted in 2012 which 
involved 135 patients with moderate to severe ileocolonic 
CD demonstrated a trend towards mucosal healing with 
adalimumab at week 12 as compared to placebo (27% 
vs 13%, respectively) as well as a significant difference 
at week 52 (24% vs 0%, respectively (P < 0.001))[30]. 
Again, this suggests 12 wk may not be sufficient in all 
patients to determine response to therapy.
Certolizumab: Certolizumab pegol is a pegylated 
humanized monoclonal antibody Fab’ fragment linked 
to polyethylene glycol that has a high affinity to tumor 
necrosis factor alpha[31]. Certolizumab was proposed as 
a potential alternative to infliximab due to its ease of 
delivery (SC as oppose to infusion) and longer half­life 
which may reduce the need for frequent dosing and risk 
for immunogenicity, theoretically[32,33]. The risks for side 
effects were presumed to be lower due to the lack of an 
Fc region which would be responsible for activating the 
compliment pathway leading to cellular apoptosis[32,33]. 
The largest phase Ⅱ trial in 2005 by Schreiber et al[33] in 
292 patients with moderate to severe CD demonstrated 
a significant dose­response relationship with clinical 
benefit demonstrated up until week 10, then lost signifi-
cance at week 12 which was presumed to be secondary 
to greater placebo rates in patients with lower CRP 
values[33]. The potential placebo effect was addressed 
in the PRECISE-Ⅰ trial which stratified 662 patients 
with moderate to severe CD based on their CRP prior 
to randomization to treatment groups[31]. Although 
response rates at week 6 and 26 were found to be mo­
destly significant, induction of remission rates were 
not. However, in patients responding to certolizumab, 
maintenance of remission was successfully demonstrated 
in the PRECISE-Ⅱ and PRECISE-Ⅲ follow­up trials 
through 5 years[34,35]. The MUSIC trial conducted in 2013 
confirmed certolizumab’s efficacy with respect to mucosal 
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(14.5% vs 6.8%, respectively), there was no significant 
difference in CDAI scores greater than 100 (CDAI­100 
score) or CRP levels between groups. However, nearly 
twice as many patients in the vedolizumab maintenance 
groups were in clinical remission as compared to the 
placebo group (39% vs 21.6% respectively). Significant 
differences in favor of maintenance therapy over placebo 
were demonstrated in the CRP and the CDAI­100 score. 
Fistulization also improved as compared to placebo in 
the small group of patients on vedolizumab every 8 wk 
(n = 17) but not in the small group taking vedolizumab 
every 4 wk[44]. Acknowledging that subjects recruited 
for this study had likely more aggressive disease than 
the aforementioned biologic-naïve anti-TNF studies 
discussed, vedolizumab is efficacious for luminal and 
possibly fistulising disease but may not provide as ef­
fective and efficient induction as compared to anti-TNF 
therapy. This has also been supported in network meta­
analyses[45]. As such, if rapid induction is required then 
physicians prescribing vedolizumab should be aware of 
the potentially slower onset of action and consideration 
for the concomitant use of faster­acting induction agents 
(e.g., corticosteroids) to bridge the patient symptoma-
tically. 
A common reason for using vedolizumab as first 
line treatment in IBD is the assumption of the re­
duced risk for infection given the attenuation of the 
immune response is localized to the gut. This has been 
previously supported in a review which included six 
trials evaluating the use of vedolizumab in UC and CD 
(2380 patients with 4811 person-years of vedolizumab 
exposure)[46]. Within this study however, 16 patients 
with CD in the vedolizumab group developed clostridium 
difficile infection as compared to none in the placebo 
group. Additionally, more patients on vedolizumab had 
gastroenteritis and developed tuberculosis infection (de­
spite negative tuberculosis screening at enrollment). 
In the aforementioned GEMINI-Ⅱ trial, vedolizumab 
also had a higher rate of infections (44.1% vs 40.2%), 
and serious infections (5.5% vs 3.0%) as compared 
to placebo[44]. Head to head trials are needed to better 
describe the risk for infection in patients taking vedoli­
zumab as compared to other biologics. 
Ustekinumab: IL-12 p35-p40 and IL-23 p19-p40 are 
two proinflammatory heterodimeric cytokines that are 
induced in the inflamed mucosa of CD patients[47,48]. 
Ustekinumab is a human monoclonal IgG1k antibody 
which blocks the P40 sub-unit of IL-12 and IL-23 on T 
cells, natural killer and antigen presenting cells[49]. Origi­
nally successful in the treatment for plaque psoriasis 
and psoriatic arthritis, ustekinumab demonstrated its 
efficacy for CD in the UNITI trials which included 1300 
CD patients with moderate to severe disease[50]. UNITI-Ⅰ 
included 741 patients whom had failed anti-TNF therapy 
due to non­response or intolerance. The induction com­
ponent of the trial revealed a significantly better clinical 
response in the ustekinumab treatment groups as com­
healing following 54 wk of therapy after evaluating 89 
patients with active endoscopic disease (ulceration in ≥ 
2 intestinal segments with a Crohn’s Disease Endoscopic 
Index of Severity (CDEIS) score ≥ 8 points)[36]. As early 
as week 10, endoscopic remission was achieved in 37% 
of patients. 
Anti-integrin
Natalizumab: Natalizumab blocks the adhesion and 
subsequent migration of leukocytes from circulation into 
the gut by binding alpha-4 integrin which is expressed 
on all circulating leukocytes except neutrophils. Origi­
nally designed for multiple sclerosis patients, natali-
zumab demonstrated good efficacy for induction and 
maintenance of remission for CD in a large meta­
analysis which included 5 trials[37]. The largest trials to 
be performed were ENACT-Ⅰ, ENACT-Ⅱ and ENCORE. 
ENACT-Ⅰ included 905 patients with CD randomized 
to either placebo or natalizumab induction groups[38]. 
Although there was a subtle but significant difference 
in the response rate favoring natalizumab (56 percent 
and 49 percent, respectively), there was no difference in 
remission rates between groups for induction. ENACT-
Ⅱ included 339 responders to natalizumab from ENACT-
Ⅰ and randomized them to maintenance therapy every 
4 wk or placebo[38]. In contrast to the first trial, signifi-
cantly higher rates of remission occurred through 36 
wk as compared to placebo (44% vs 26%). Induction 
of remission was reassessed in the ENCORE study 
which included 509 patients with CD evaluated through 
3 induction doses over 8 wk. At week 12, a greater 
proportion of patients on natalizumab were in remission 
as compared to placebo, 28% vs 16% respectively[39].  
Although natalizumab demonstrated good efficacy 
in luminal CD, concerns related to serious infection sur-
faced. In an open-label extension of the ENACT-Ⅱ trial, 
one patient died from JC virus­associated progressive 
multifocal leukoencephalopathy (PML)[40]. The association 
with PML and natalizumab was described in two other 
case reports on patients receiving treatment for multiple 
sclerosis[41,42]. Since the estimated risk for PML is 1 
per 1000 patients, JC virus antibody testing should be 
considered if natalizumab will be used in IBD. 
Vedolizumab: Vedolizumab reduces lymphocyte mig­
ration into the gut by antagonizing the α4β7 integrin 
mediated reactions. In contrast to natalizumab it does 
not act on α4β1 integrin, which is involved in brain lym-
phocyte trafficking, thus may have lower risk for PML[43]. 
Efficacy for its use as an induction and maintenance 
agent in CD was demonstrated in the GEMINI-Ⅱ trial[44]. 
In the induction component of the trial, 368 patients 
were randomized to placebo or vedolizumab and 747 
patients received open­label vedolizumab. Approximately 
50% of all patients had failed at least one anti-TNF prior 
to enrolling in the study. Although clinical remission was 
achieved in a significantly greater proportion of patients 
taking vedolizumab as compared to placebo at week 6 
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pared to placebo (34% vs 22%, respectively). UNITI-
Ⅱ included 628 patients whom were anti-TNF naïve but 
failed conventional immunosuppressive therapy due 
to poor response or intolerance. The UNITI-Ⅱ cohort 
also had a significant improvement in their CDAI scores 
for induction by approximately 25% as compared to 
placebo. Patients receiving maintenance therapy every 8 
wk and every 12 wk demonstrated a significantly greater 
remission rate at week 44 as compared to placebo (53% 
and 49% vs 36%, respectively). Of note, the secondary 
analyses demonstrated a non­significant difference in 
CDAI scores compared to placebo in the UNITI-Ⅰ group 
as compared to the UNITI-Ⅱ group, albeit the trend still 
favored ustekinumab therapy[50]. Lack of significance is 
most likely due to a lack of power to properly evaluate 
the difference amongst sub-groups, however this trend 
is expected; patients in UNITI-Ⅰ have more refractory 
disease thus less likely to respond to ustekinumab as 
compared to the biologic-naïve patients in UNITI-Ⅱ. 
Significant improvements in fecal calprotectin and CRP 
were also noted and able to be seen as early as 3 wk sup­
porting its usefulness in acute severe flares. 
UC
Anti-TNF agents
Infliximab: The first two large-scale studies to assess 
the therapeutic potential of infliximab were the ACT 1 
and ACT 2 trials published in 2005, prior to this, biologic 
therapy for UC was not established[51]. ACT 1 evaluated 
364 patients with moderate to severe UC following their 
induction and maintenance dosing until 54 wk. ACT 2 
evaluated the same number of patients and maintained 
the same induction, maintenance and follow-up regimen 
as ACT 1 except maintenance dosing ceased after 
22 wk. Nearly 60% of patients in both cohorts were 
steroid dependent. In both studies, a significant clinical 
response was demonstrated with remission occurring 
in approximately 35% and 31% of patients taking 
infliximab as compared to 15% and 6% of patients 
on placebo at week 8 in ACT 1 and ACT 2 studies, 
respectively. Sustained remission was achieved over 
the study period in approximately 20% of patients on 
infliximab as compared to 5% of patients in the placebo 
group. Additionally, a greater proportion of patients 
were able to be weaned off their steroids following the 
initiation of infliximab. Mucosal healing, considered to 
be the greatest risk factor for malignancy, was markedly 
improved throughout the study period and significantly 
better than placebo as early as week 8, approximately 
60% vs 30% respectively. No difference between the two 
doses prescribed, 10 mg/kg and 5 mg/kg, was identified 
with respect to efficacy[51].
Given the toxicity associated with cyclosporine and 
limited therapies available, GETAID compared the ef-
ficacy of infliximab against cyclosporine in an open­
label RCT involving 115 patients with severe ulcerative 
colitis whom had failed high dose intravenous steroid 
therapy. The results were positive for both agents with no 
significant difference in treatment failure or side effects 
between the infliximab and the ciclosporin groups (54% 
vs 60%, respectively)[52]. 
Adalimumab: Five years following the approval for 
infliximab use in UC, adalimumab became the second 
biologic approved for use in UC based on the results from 
the ULTRA trials. ULTRA 1 utilized two different induction 
regimens (160/80 mg vs 80/40 mg SC at weeks 0 and 2 
followed by 40 mg every 2 wk) to evaluate if adalimumab 
was effective in 186 moderate to severe UC patients[53]. 
At week 8, 19% vs 9% were in remission in the 160/80 
mg group as compared to placebo, respectively. As 
noted in the CD trials, a ceiling effect was not achieved 
thus the optimal dose is still under investigation. ULTRA 
2, which included 518 patients with moderate to severe 
UC, was conducted to evaluate the long-term efficacy 
of adalimumab as a maintenance agent[53]. Following 
1 year, remission was achieved in 17% of patients on 
regular maintenance dosing as compared to 9% of pa­
tients in the placebo group. Similarly, mucosal healing 
was also higher in the adalimumab group as compared 
to placebo at both week 8 and 52 follow-up intervals, 
41% and 25% vs 32% and 15%, respectively. This study 
also demonstrated that biologic naïve patients were 
more likely to achieve clinical remission as compared 
to patients previously on infliximab (Week 8: 21% vs 
9% and Week 52: 22% vs 10%, respectively), which 
highlights prior biologic use as a potential risk factor 
for difficult to treat or aggressive disease. Long­term 
maintenance therapy using adalimumab was further 
evaluated over 4 years in ULTRA 1 and 2 trials as well 
as in an open­label study (ULTRA 3)[54]. With respect to 
patients observed as nonresponder imputation (NRI), 
25% and 28% of the 199 patients from ULTRA 1 and 
2 whom were still on adalimumab at the 4 year follow-
up maintained clinical remission and mucosal healing 
respectively. In contrast, the ULTRA 3 open-label trial 
demonstrated clinical remission and mucosal healing 
rates to be considerably greater (64% and 60%, re-
spectively), albeit difficult to compare in the absence of 
randomization. 
Golimumab: Golimumab is a fully human monoclonal 
immunoglobulin delivered subcutaneously which targets 
a unique epitope on the TNF molecule as compared to 
infliximab and adalimumab. The PURSUIT trials which 
evaluated 1064 biologic naive patients with moderate to 
severe UC were responsible for establishing regulatory 
approval for it in 2014. The induction trial, PURSUIT-SC, 
revealed a significantly greater proportion of patients in 
clinical remission following 6 wk using 200/100 mg and 
400/200 mg induction doses as compared to placebo, 
51% and 55% vs 30% respectively[55]. The extension of 
this trial, PURSUIT-M, which included 464 patients with 
moderate to severe UC whom had responded favorably 
to golimumab in the induction trial also demonstrated 
greater efficacy than placebo at maintaining clinical re-
mission following 54 wk. At study end, 42% of patients 
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taking golimumab 100 mg every 4 wk were found to 
be in clinical remission as compared to 27% of patients 
taking placebo[56]. The rate of mucosal healing was signif­
icantly greater for patients taking golimumab in both the 
induction and maintenance studies, the differences were 
able to be appreciated as early as 2 wk. Golimumab, 
although not formally assessed in clinical trials, has been 
reported to be efficacious as a second and third-line anti-
TNF agent in real life settings[57]. 
Anti-integrin agent
Vedolizumab: GEMINI-1 evaluated the efficacy of vedoli-
zumab in a treatment resistant group of 895 moderate 
to severe UC patients (approximately 40% of patients 
failed ≥ 1 anti-TNF therapy)[58]. In the induction phase 
of the trial, 17% of patients taking vedolizumab were in 
clinical remission as compared to 5% of patients taking 
placebo by week 6. Mucosal healing was also nearly 
twice as apparent in patients taking vedolizumab as 
compared to placebo (41% vs 25% respectively). At 52 
wk, clinical remission was maintained in approximately 
44% of patients taking vedolizumab as compared to 
16% of patients on placebo. No significant difference was 
identified between treatment groups receiving every 4 or 
8 wk dosing regimens. In contrast to GEMINI-Ⅱ for CD, 
there was no difference in infection rates in the treatment 
group as compared to placebo[44,58]. 
SMALL MOLECULES
JAK inhibitors 
Tofacitinib: Tofacitinib is a new oral medication which 
suppresses cytokine signalling in mucosal immune cells 
by inhibiting janus kinase’s 1 and 3 (JAK 1 and 3). The 
oral route of administration and ability to target multiple 
cytokine pathways makes JAK inhibitors an attractive 
therapeutic option.
Although the efficacy for tofacitinib has not been 
established in CD yet, it has been established in UC 
as demonstrated by the OCTAVE trials[59]. Of the 905 
patients with moderate to severe UC randomized to treat­
ment in the induction trials, approximately 18% achieved 
clinical remission as compared to 6% of patients in the 
placebo group at 8 wk. Onset to effect was rapid, with 
improvements in their partial mayo score demonstrated 
as early as 2 wk. Although over 50% of patients within 
the induction groups had prior exposure to anti-TNF 
therapy, the treatment effect was similar in comparison 
to patients whom were biologic naïve despite OCTAVE’s 
more stringent criteria for clinical remission as compared 
to the aforementioned trials (i.e., partial mayo rectal 
bleeding subscore of 0). The OCTAVE-Sustain extension 
trial, which included 593 patients who had a clinical re-
sponse to induction therapy, also demonstrated good 
maintenance of remission after 52 wk in both 5 mg and 
10 mg twice daily treatment groups as compared to 
placebo (34% and 41% vs 11%, respectively). Mucosal 
healing and steroid­free remission was achieved and 
maintained in a similar proportion of patients. With re­
spect to adverse events, serious infections occurred 
more frequently in the induction but not maintenance 
trial. However, herpes zoster infection did occur more 
frequently in the tofacitinib 10mg maintenance group as 
compared to placebo[59]. Of note, tofacitinib received a 
recommendation for the treatment of UC by the GIDAC­
FDA in March 2018 a final decision is anticipated by June 
2018[60].
BIOSIMILARS
According to the FDA, a biosimilar is defined as a bio-
logical product that is highly similar to the reference 
product notwithstanding minor differences in clinically 
inactive components which result in no clinically mea­
ningful differences in the purity, safety and efficacy of 
the product[61]. The use of biologic anti­inflammatory 
medications is increasing and the cost has become a 
significant economic burden on many national health­
care systems around the world[62]. In Canada, the 
growth of Canadian sales of biologic anti­inflammatory 
drugs has nearly doubled since 2010. The top­selling 
biologic, remicade (infliximab), has cost the Canadian 
Government $224 million in 2015 and $4.8 billion since 
it was approved 10 years ago. Based on a Market Intel­
ligence Report published by Health Canada, the use of a 
biosimilar such as Inflectra could have resulted in a $41.7 
million reduction in drug expenditures in 2015[62]. Several 
biosimilars to remicade (flixabi, inflectra, remsima) and 
adalimumab (cyltezo and imraldi) have already been 
approved for use in IBD.
Infliximab-dyyb (or CT-P13), was the first biosimilar 
for remicade (infliximab) to be approved and has the 
greatest amount of ‘real world’ observational data eval­
uating its efficacy and safety[63]. Infliximab­dyyb was 
first approved in South Korea and thereafter in Europe 
in 2013 following the results of two large randomized 
and double­blind clinical studies evaluating its safety 
and efficacy in rheumatoid arthritis as compared to 
remicade, PLANETRA and PLANETAS[64,65]. No significant 
differences were found with respect to safety, efficacy 
and immunogenicity thus it was approved for use in all 
labelled indications remicade was approved for. However, 
small retrospective studies in IBD have demonstrated 
mixed results[66­68]. A larger prospective nationwide multi­
center study performed in Hungary involving 126 CD and 
84 UC patients reported excellent induction rates[69]. At 
week 14, 81% of patients with Crohn’s disease and 78% 
of patients with ulcerative colitis had a clinical response 
(CDAI reduction > 70) and 54% and 59% respectively, 
were in clinical remission (CDAI < 150). Comparable 
results were also seen in another large observational 
cohort study including 313 CD and 234 UC patients[70]. 
Response rates at 8 wk were greater than 90% for all 
patient groups, including patients whom switched from 
remicade to infliximab-dyyb. At week 24, response 
rates were 73.7%, 62.2% and 78.9% for biologic naïve, 
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pre-exposed and switched respectively. The efficacy, 
immunogenicity and safety profiles in both studies were 
considered comparable to that of the originator drug 
infliximab.
To date, studies which have evaluated switching from 
originator to biosimilar have been largely positive[71,72]. 
The longest evaluation period occurred over 52 wk in 
the NOR-SWITCH study which was a randomised, non-
inferiority, double-blind, phase 4 trial involving 482 
patients across 40 Norwegian centres with various infla-
mmatory diseases maintained in remission on infliximab 
for at least 6 mo. Of the 482 patients, 155 (32%) and 
93 (19%) were CD and UC respectively[73]. At study end, 
there was no difference in disease worsening, safety or 
immunogenicity amongst any of the groups. Although 
switching therapies in the setting of controlled disease 
would be a reasonable option and is supported by the 
evidence as well as the European Crohns and Colitis 
Organization; switching in the setting of failing the origi-
nator drug would be ill­advised[71]. Ben-Horin et al[74] 
studied the cross reactivity of antibodies to remicade and 
infliximab­dyyb in 125 patients with IBD and healthy 
individuals as negative controls. They demonstrated that 
anti-remicade antibodies recognize and inhibit infliximab-
dyyb as well. These results suggested that there was 
similar immunogenicity and shared immunodominant 
epitopes. Although this supported the safety of biosimilars 
and the use of the same assay as the originator drug to 
detect antibodies, this study also supported not using the 
biosimilar in the setting of originator failure[71,74,75].
Evolution of treatment strategies of IBD and positioning 
currently approved biologics and small molecules in 
clinical practice
As the therapeutic armamentarium for IBD continues 
to expand, so follows the complexity associated with 
managing IBD patients in clinical practice. The needs 
for algorithms are required in order to assist health care 
practitioners determine the relative positioning of each 
agent and their use in combination with other therapies. 
Until the results of head to head biologic and small 
molecule trials become available, we can only speculate 
the positioning of therapeutic agents based on the 
current available literature as summarized in this section 
(Table 1). 
Positioning the ‘old’ biologics: Anti-TNFs first, alone or 
in combination?
As newer and more targeted therapies in IBD become 
available, questions related to maintaining anti-TNF 
agents as first line therapy arise. Based on decades of 
data, anti-TNFs currently provide the best long-term 
evidence of efficacy in CD and UC, with a known safety 
profile. They are effective for both induction and main-
tenance therapy, decrease corticosteroid exposure and 
promote sustained mucosal healing[76,77]. The most im­
portant safety concern is the risk of serious infection. 
However, in younger patients without co-existing medical 
problems, this risk is fairly low[78].
Comparing efficacy of TNF inhibitors is difficult due 
to the lack of high-quality, head-to-head trials (Table 2). 
Network meta-analyses indirectly comparing anti-TNF 
agents have reported mixed results[45,79-81]. Based on ‘real 
world’ data, an analysis of retrospective and comparative 
effectiveness database studies revealed subtle diffe­
rences regarding hospitalisation and surgery rates as 
well as the steroid sparing effect between infliximab 
and adalimumab, favouring infliximab at currently re-
commended doses. Of note, clinical trials of higher-dose 
adalimumab for both UC and CD are currently under­
way[82,83].
Deciding between which anti-TNF agent to use de-
pends on the clinical circumstances, treatment history 
and patient preference. In the absence of head­to­head 
comparisons, there exists few specific scenarios in which 
the evidence supports the use of specific anti-TNF agents. 
In the setting of a hospitalized patient with severe 
UC, only infliximab has demonstrated its efficacy as a 
‘rescue’ therapy[84]. Patients with perianal disease can 
benefit from either infliximab or adalimumab, albeit the 
evidence is based on a post­hoc analysis for adalimumab 
and lacking for other anti-TNF agents[23,85]. Golimumab 
Medication Route of administration (Ⅳ, SC, PO) Approved dose
Infliximab Ⅳ Induction: 5-10 mg/kg (weeks 0, 2, and 6)
Maintenance: 5-10 mg/kg every 4-8 wk
Adalimumab SC Induction: 160 mg (week 0), 80 mg (week 2)
Maintenance: 40 mg every 7-14 d
Golimumab SC Induction: 200 mg (week 0), 100 mg (week 2)
Maintenance: 100 mg every 4 wk
Certolizumab SC Induction: 400 mg (weeks 0, 2, and 4)
Maintenance: 400 mg every 4 wk
Vedolizumab Ⅳ Induction: 300 mg (weeks 0, 2, and 6)




< 55 kg: 260 mg
55-85 kg: 390 mg
> 85 kg: 520 mg
Maintenance: 90 mg every 8 wk
Table 1  Currently approved biologic treatments for inflammatory bowel diseases[16,117,118]
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has demonstrated efficacy in UC as a second or third 
line anti-TNF agent in small cohorts of patients but not 
for CD. Similarly, certolizumab can be considered in the 
same context for CD but lacks evidence for UC. Ease of 
administration may influence one’s decision thus patients 
who would rather less frequent dosing may prefer the 
Ⅳ infusion infliximab as compared to the other anti-TNF 
agents which are delivered SC by the patient. 
The relatively high costs of anti-TNFs and the expi-
ration of patents have triggered the development of 
biosimilar monoclonal antibodies. Multiple regulatory 
agencies have approved the use of biosimilars in IBD 
based on extrapolation of data on safety and efficacy. 
Since then, real-word data and randomised controlled 
trials on switching from originator to biosimilar infliximab 
has shown similar results in terms of efficacy and 
safety[72]. Following the introduction of vedoluzimab and 
ustekinumab, anti-TNF therapy may not be the first-line 
biologic agent in all IBD patients. However, the lower cost 
of biosimilars probably makes the use of anti-TNF agents 
still very attractive.
Optimizing the efficacy of the initial anti-TNF therapy 
prior to switching to another biologic, either in or out of 
class, is a critical principle when managing IBD patients. 
Studies have repeatedly demonstrated that patients fai­
ling their first biologic have poorer outcomes following 
initiation of their second or third biologic[50,58]. The ability 
to differentiate the cause for a loss of response to anti­
TNF therapy has been facilitated with therapeutic drug 
monitoring (TDM)[86]. Based on TDM results, an educated 
decision regarding dose optimization and switching 
in or out of class can now be determined[16,87]. How-
ever, the frequency of TDM is still up for debate. Few 
retrospective studies have demonstrated benefit with 
proactive TDM[88,89]. The recent multicentre prospective 
RCT involving 167 patients with active CD, TAILORIX, 
demonstrated that there was no benefit in patients re-
ceiving infliximab dose escalation based on TDM as com-
pared to clinical scoring[89]. Although more patients in the 
clinical dose escalation group received dose escalation as 
compared to the TDM group, thus the benefit seen from 
the clinical group may be over-inflated. Similarly, the 
TAXIT study, which was a 1 year RCT involving 178 CD 
and 85 UC patients performed at a single tertiary referral 
center, did not find benefit in proactive vs reactive (i.e., 
symptom based) TDM[88]. However, the results from the 
TAXIT study should be interpreted with caution since 
dose optimisation occurred in both groups at study start. 
Prospective, multi-center studies are needed to further 
investigate the positioning of TDM. 
The decision to initiate combination therapy involves 
balancing the benefits of improved efficacy and lower 
immunogenicity of therapy against the heightened 
risks for infection and malignancy. The SONIC trial re-
vealed the steroid­free remission rate in CD patients at 
week 26 was significantly greater in the combination 
azathioprine and infliximab group as compared to in­
fliximab or azathioprine alone (57% vs 44% vs 30%, 
respectively)[14]. The SUCCESS trial, which was a 16 
week RCT involving 239 patients with moderate to se­
vere UC, revealed similar results. Steroid-free remission 
was achieved in 40% of patients on dual therapy as com-
pared to 22% and 24% on infliximab and azathioprine 
monotherapy, respectively[90]. Supporting this strategy 
was the open label prospective DIAMOND study which 
evaluated 176 Japanese patients with CD over 52 wk. 
This study demonstrated that the efficacy of using 
dual therapy was not limited to only infliximab but 
also to adalimumab. Mucosal healing was significantly 
better in the combination group as compared to the 
azathioprine monotherapy group at week 26 (84% vs 
64%, respectively)[91]. Although the difference in clinical 
remission was not significant, likely due to a small 
cohort and lower thiopurine dosing, a trend was main-
tained in favor of combination therapy. The infection 
and serious complication risks were not greater on dual 
therapy as compared to monotherapy in either of the 
aforementioned studies. In contrast, the SONIC trial 




1Infliximab[20,22,51,119] Chimeric monoclonal antibody x x x x x
Adalimumab[26,28,54,120,121] Fully human monoclonal antibody x x x x x
Certolizumab[31,122,123] Pegylated humanized monoclonal antibody Fab' fragment x +/- x x
Golimumab[57,122,124] Fully human monoclonal antibody x x x
Anti-integrin
4Natalizumab[39] Chimeric monoclonal antibody against α4 integrin x
3Vedolizumab[46,96] Chimeric monoclonal antibody against α4β7 integrin x x +/-
Ustekinumab[50,125,126] Fully human monoclonal antibody against P40 sub-unit of 
IL-12 and IL-23
x +/- x x
Table 2  Biologic agents which have demonstrated efficacy in inflammatory bowel diseases and rheumatology
1Infliximab is the only biologic which has been evaluated to be an effective ‘rescue’ agent. Evidence is lacking for the remaining biologics; 2Improvement 
in fistulizing disease was evaluated as a primary outcome only in infliximab. Efficacy was otherwise determined indirectly from secondary outcomes, 
subgroup analyses and small scale studies for the remaining biologics; 3Consider the use of vedolizumab as a first-line biologic agent in patients at high risk 
for infectious complications. Vedolizumab has a slower onset of action (approximately 6-8 wk) as compared to alternate biologics; 4Use of natalizumab is 
contraindicated if the patient is JC virus antibody positive due to the risk of progressive multifocal leukoencephalopathy. UD: Ulcerative colitis; CD: Crohn’s 
disease.
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demonstrated the lowest risk for infection to be present 
in the dual therapy group (3.9%) as compared to the 
infliximab or azathioprine monotherapy groups (4.9% 
and 5.6%, respectively). This suggests that poorly 
controlled disease is a stronger risk factor for infection 
instead of intensified immunosuppression. Ultimately, 
the risk for hepatosplenic T­cell lymphoma (especially 
in young/adolescent males after 2 years of therapy), 
myelosuppression and opportunistic infections must be 
weighted individually[92,93]. Consideration can be made to 
initiating therapy with both combined thiopurine and anti­
TNF therapy than stopping thiopurine therapy after 6 mo 
in the setting of clinical and biochemical remission and a 
therapeutic drug level, which has been supported in the 
literature[94,95].
Positioning ‘new’ agents: First or second-line? 
Vedolizumab has emerged as a first-line agent for induc-
tion of remission for moderately active UC patients 
failing conventional therapy[58]. In CD, clinicians should 
be aware of the potentially slower onset of action of 
vedolizumab. Concomitant use of corticosteroids may be 
necessary during the induction period. For these reasons, 
anti-TNFs or ustekinumab may be more favourable first 
line choices in CD patients with severe disease activity 
at present. There is also no considerable data from RCTs 
on the efficacy of vedolizumab in fistulizing CD and 
acute severe UC. Ongoing phase Ⅳ trial will determine 
its effectiveness[96]. Vedolizumab is currently being posi­
tioned in some jurisdictions as a second­line biologic 
agent following anti-TNFs, although the ongoing LOVE 
studies are evaluating the use of vedolizumab in early 
vs. late UC and CD[97,98]. Given their effectiveness in the 
medium to long term and the favourable safety profile, 
it is expected that gut­selective anti­integrin agents will 
increasingly be used as maintenance therapy or even as 
part of a combination biological therapy. A clinical trial 
evaluating the efficacy of adalimumab, methotrexate and 
vedolizumab triple combination therapy is ongoing[99].
Ustekinumab is the most recently approved biologic 
agent for CD[50]. Presently, there is no data available 
describing its efficacy in UC or fistulising CD. An indirect 
comparison amongst the anti-TNF and UNITI trials sug-
gests ustekinumab may be safer and have a lower rate of 
immunogenicity which may make it the preferred biologic 
for some CD patients[77]. More comprehensive data on 
efficacy in certain patient subgroups and mucosal healing 
is needed.
Finally, tofacitinib is a small molecule awaiting final 
approval for the treatment of UC[59,60]. Their oral route 
of administration makes them particularly attractive. 
Their safety profile has been suggested to be similar to 
that of thiopurines. Due to their mechanism of action, 
they are not limited by immunogenicity and subsequent 
loss of response. Their positioning and use as mono­ or 
combination therapy has yet to be elucidated. 
The evolution of treatment strategies and objective 
monitoring: Early aggressive or tailored therapy?
The introduction of highly effective therapies early in 
the disease course alongside objective patient moni­
toring can modify the disease trajectory and reduce 
morbidity. However, it is also important to recognize 
that approximately 20% of patients with IBD may have 
an indolent disease course, and available population-
based data suggests that approximately half of patients 
with CD can be symptomatically controlled 10 years 
after diagnosis[100,101]. Risk stratification can guide early 
introduction of highly effective therapy in patients with 
a poor prognosis and prevent overtreatment in low­
risk patients. Unfortunately, current patient stratification 
relies on clinical factors. Most of these are indicators 
rather than predictors of a complicated disease course 
(e.g., presence of perianal disease, age < 40 years old at 
diagnosis and need for steroids during the first flare)[102]. 
Molecular makers for predicting an aggressive phenotype 
have yet to be identified but studies are ongoing[103,104]. 
In the absence of objective predictors for disease 
severity, studies have attempted to better elucidate 
the risks and benefits of aggressive therapy. The TOP­
DOWN trial was the first to assess and compare dif-
ferent treatment algorithms in IBD[105]. Treatment­naïve 
early CD patients were randomly assigned to receive 
early aggressive therapy (‘top­down’) with an immu­
nosuppressant and anti-TNF agent or less aggressive 
(‘step­up’) therapy with steroids and a possible transition 
to immunosuppressant and biologics if necessary. The 
authors found that the ‘top­down’ strategy was more 
effective than the conventional ‘step­up’ strategy for 
achieving corticosteroid­free remission at week 52 
(61.5% vs 42.2%, P = 0.027). Similar conclusions were 
demonstrated in both the SONIC and UC-SUCCESS trials 
whereby the efficacy of therapy was improved despite 
comparable adverse events between groups. 
The strengths of objective patient monitoring are 
becoming more evident as study designs continue to 
improve and include more objective markers of disease 
severity and response to therapy. An example is the 
cluster randomisation trial, REACT[106]. In this trial, 1982 
patients with CD were randomized to receive either 
algorithm­based treatment optimization vs. conventional 
management (therapeutic decisions based on community 
physician assessment). The composite endpoint of hospi­
talization, surgery and serious disease related compli-
cations was lower in patients treated with the algorithm­
based strategy at 24 mo (27.7% and 35.1%, hazard 
ratio: 0.73, 95%CI: 0.62 to 0.86, P < 0.001), despite 
no differences in serious drug­related adverse events 
as compared to the conventional treatment group. In 
UC, evidence is less straightforward on whether ‘top-
down’ therapy alters the long­term disease outcomes. 
Although several studies have shown that the severity 
and extent of UC at diagnosis may have a major impact 
on the subsequent course of the disease with elevated 
risks of recurrent hospitalization, colectomy, cancer and 
mortality[101,107,108]. In a population­based inception cohort 
from Norway, the extent of disease, need for systemic 
steroids and high CRP at diagnosis were independently 
associated with colectomy[109]. Consequently, patients pre-
senting with extensive colitis and signs of severe disease 
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at diagnosis could benefit from top-down therapy.
‘Treat to target’, a strategy that uses objective clinical 
and biochemical outcome measures to assist clinicians 
in making decisions related to modifying therapy, has 
been gaining popularity since the REACT study demon-
strated that disease activity correlates relatively poorly 
with objective measures of inflammation, and clinical 
remission in the absence of mucosal healing may not 
necessarily decrease the risk of future complications 
in CD[106]. The CALM study supported this logic as well 
and demonstrated that early and stringent control of 
disease using objective markers of inflammation (e.g., 
CRP and fecal calprotectin) was efficacious and safe 
in their sample population of 244 patients with CD[18]. 
Their primary end-point, mucosal healing at 48 wk, was 
achieved in 46% vs 30% of the patients in the ‘tight 
control’ group as compared to the ‘clinical management’ 
group. Deep, biological and steroid-free remissions 
were greater in the ‘tight control’ group as well, whilst 
the adverse events not significantly different between 
groups. The recent systematic review and expert opinion 
of 28 IBD specialists on ‘Selecting Therapeutic Targets in 
Inflammatory Bowel Disease’ (STRIDE) also suggested 
the importance of using objective markers and recom­
mends that therapeutic targets for CD and UC should 
move away from composite disease activity indices 
to separate patient­reported outcomes and objective 
measurements of inflammation (Table 3)[19]. However, 
the open­label multicentre RCT ‘CALM’ suggested that 
biomarkers such as fecal calprotectin be considered as ad­
ditional targets to therapy in their cohort of 244 patients 
with active CD. Besides acting as a treatment target, 
biomarkers can facilitate the monitoring of a patient. For 
example, elevated c-reactive protein or fecal calprotectin 
should prompt further endoscopic and/or radiologic eval-
uation irrespective of clinical scores. Although intensified 
regimens are efficacious, they are also more likely to 
encounter difficulties with patient compliance. Additional 
guidance regarding the use of endoscopic findings as 
treatment targets will come following the completion of 
the REACT-Ⅱ prospective trial.
FUTURE PERSPECTIVES
Data obtained from head to head biologic and small 
molecule trials will eventually be applied to clinical prac­
tice in order to better individualize and optimize therapy. 
The determination of which therapies can be combined 
best will be further elucidated as well. For instance, 
combining anti-TNF therapy with vedolizumab is being 
evaluated in studies for patients with refractory disease 
because it combines a rapidly acting systemic agent with 
a slower acting gut­specific therapy. The development 
of oral medications with specific targets (e.g., filgotinib) 
will open the door to a large range of potential thera­
peutic combinations which will enable therapy to be 
individualized further[110]. Specific therapies such as anti-
fibrotics, SMAD7 inhibitors, sphingosine 1-phosphate 
receptor modulators and phosphodiesterase inhibitors are 
quickly making their way through trial phases and can be 
expected to hold a place in the IBD armamentarium in 
the near future[111­113]. As in Oncology, omics will enable 
us to determine which patients are at greatest risk for a 
complicated disease course thus provide a rationale for 
initiating intensified immunotherapy at diagnosis and 
individualize therapy best[114]. Molecular imaging and pre­
treatment genetic and biomarker analysis may be able to 
predict response to a proposed therapy in the future and 
are currently being investigated[103,104,115,116].
CONCLUSION
As the quality of trial designs improved over the decades, 
so followed our understanding of IBD. This has enabled 
Crohn’s disease Ulcerative colitis
The consensus target is a combination of:
Clinical/1PRO remission defined as resolution of abdominal pain and 
diarrhea or altered bowel habits which should be assessed every 3 mo until 
resolution then 6-12 mo thereafter.
and 
Endoscopic remission2 defined as resolution of ulceration at ileocolonoscopy 
which should be assessed at 6-9 mo intervals during the active phase
Clinical/1PRO remission defined as resolution of rectal bleeding and 
diarrhea or altered bowel habits which should be assessed every 3 mo until 
resolution then 6-12 mo thereafter.
and 
Endoscopic remission2 defined as resolution of friability and ulceration at 
flexible sigmoidoscopy or colonoscopy3 which should be assessed at 3 mo 
intervals during the active phase








Table 3  Recommendations for treating to target in Crohn’s disease by the International Organization for the Study of Inflammatory 
Bowel Diseases[19]
1Patient reported outcomes; 2When endoscopy cannot adequately evaluate inflammation, resolution of inflammation as assessed by cross-sectional imaging 
can be substituted; 3While Mayo subscore of 0 may be defined as the target, there is currently insufficient evidence to recommend it in all patients; only 
Mayo subscore of 0-1 can be systematically recommended in practice.
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us to tailor therapy and develop effective treatment 
algorithms using clinical symptomps/PROS, biomarkers 
and endoscopic indices to help guide therapy. Anti-TNF 
therapy remains an important component of IBD therapy 
with the most real­life evidence and should be considered 
as first­line therapy in patients with complicated CD 
and in acute-severe UC. Novel mono- and combination 
therapies have only begun to be approved and offer 
the ability to tailor therapy further. However, clinicians 
will be faced with important challenges in defining the 
optimal use of these new therapies and their relative 
position in treatment algorithms. The next generation of 
clinical trials will need to ascertain the answers to these 
questions.
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